Abstract��OBJECTIVE Decision tree is established for the interpretation of vancomycin(VCM) serum concentration, and is applied in clinical practice. METHODS Decision tree is applied for VCM interpretation based on the serum concentration and the course of disease. The Bayesian feedback procedure of population pharmacokinetics model is utilized for adjustment of VCM dosage, which is helpful for VCM individualization. RESULTS Decision tree is applied for the interpretation of VCM serum concentration, which could provide basis for the establishment of VCM dosage regimen. CONCLUSION The pattern of applying decision tree to interpretate VCM serum concentration is helpful for individualized dosing, which would improve the effect and reduce the relative side effect of VCM.
��ɺ�������⣬���������κ��Σ�����. ���ھ����������ù��ѪҩŨ�Ƚ����ʵ��[J]. �й�ҩѧ��־, 2016, 51(19): 1710-1713.
HUANG Shan,LIN Wei-wei,WANG Chang-lian, SONG Hong-tao,JIAO Zheng. Interpretation of Vancomycin Serum Concentration Based on Decision Tree and Clinical Pracice. Chinese Pharmaceutical Journal, 2016, 51(19): 1710-1713.
HE X R, LIU Z H, JI S M. Population pharmacokinetics of vancomycin and prediction of pharmacodynamics in the Chinese people . Acta Pharm Sin(ҩѧѧ��), 2014, 49(11):1528-1535.
[2]
RYBAK M J. The pharmacokinetic and pharmacodynamic properties of vancomycin . Clin Infect Dis, 2006, 42 (suppl 1):35-39.
[3]
CHARLES P G, WARD P B, JOHNSON P D, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis, 2004, 38(3):448-451.
[4]
WONG-BERINGER A, JOO J, TSE E, et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy . Int J Antimicrob Agents, 2011, 37(2): 95-101.
[5]
GOULD F K, 0-BRINDLE R, CHADWICK P R, et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom . J Antimicrob Chemother, 2009, 63(5):849-861.
[6]
LAI D F, CHEN X D. Early diagnosis and prediction of portal hypertension complicated with portal vein thrombosis spleen resection based on the decision tree. J Huzhou Teach Coll(����ʦ��ѧԺѧ��), 2013, 35(6):69-73.
[7]
SUN X L, CHE L J, YU J. Based on ID3 algorithm of decision tree for the forecast of hospitalization days. J Mathematical Med(����ҽҩѧ����־), 2011, 24(4):382-384.
[8]
LIN W W, WU W, ZHENG J, et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur J Clin Pharmacol, 2016, 72(1):29-37.
[9]
HE X R, LU W, ZOU D, et al. Advance on population pharmacokinetic models of vancomycin. Chin Pharm J(�й�ҩѧ��־), 2013, 48(2):2075-2080. KAZUAKI M, YOSHIO T, NORIO O, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother, 2013, 19(3):365-380. RYBAK M, LOMAESTRO B, ROTSCHAFER J C, et al. Therapeutic monitoring of vancomycin in adultpatients: a consensus review of the American society of health-system pharmacists, the infectiousdiseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm, 2009, 66(1):82-98. HU J L, ZHANG J. Research up dates of vancomycin nephrotoxicity. Chin J Infect Chemother(�й���Ⱦ�뻯����־), 2013, 13(5) :394-399. LODISE T P, PATEL N, LOMAESTRO B M, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis, 2009, 49(4):507-514. SAKOULAS G, GOLD H S, COHEN R A, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus(MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother, 2006, 57(4):699-704. CHEN B, YANG W H. Application of population pharmacokinetics in the therapeutic drug monitoring of vancomycin. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2011, 27(9):713-717. YE Z K,LI X G,ZHAI S D.Therapeutic drug monitoring of vancomycinin chian: current status andevaluation. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2013, 29(7):545-548.
2016, Vol. 51 
